Compare Aegon Ltd. (AEG) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs Illumina, Inc. — how do they compare? Aegon Ltd. trades at $9.4 (market cap $14.01B), while Illumina, Inc. trades at $191.5 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 2.1× Aegon Ltd.'s market cap, and Aegon Ltd. pays a 4.94% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| AEG | ILMN | |
|---|---|---|
Market Cap | $14.01B | $29.12B |
Sector | Financials | Health |
52-Week High | $9.53 | $205.10 |
52-Week Low | $6.79 | $91.00 |
Enterprise Value | $15.16B | $30.48B |
Dividend Yield | 4.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.415, down 0.37% on the day, with a bullish technical signal from moving averages. The company reported mixed recent earnings, beating expectations in Q2 and Q3 2025 but missing in Q4. Revenue for 2024 was $19.52 billion, with net income of $688 million. A dividend of $0.25 per share is scheduled for payment in July 2026. The balance sheet shows total assets of $327.39 billion and a declining debt-to-asset ratio, improving from 2.43 in 2020 to 1.46 in 2024.
AEG presents a moderate investment case with a low P/E of 13.54 and P/S of 0.57, suggesting potential undervaluation. Analyst sentiment is mixed with a 27.78% buy rating. Key risks include volatile cash flows and execution of strategic shifts, such as the relocation to the U.S. and partnership developments. The stock's outlook hinges on sustained profitability and successful implementation of corporate simplifications.
Illumina (ILMN) trades at $192.57, up 0.4% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue remains stable around $4.3B, and profitability has improved significantly, with a net income margin of 19.57% in 2025. The company maintains robust cash flow from operations of $1.08B in 2025.
The outlook is mixed; strong fundamentals and analyst buy ratings support upside to the $201.58 consensus target, but technical weakness and high valuation ratios pose near-term risks. Key opportunities include sustained earnings beats and AI initiatives, while risks involve competitive pressures and execution challenges in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
